Iryna Kriachok

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 258 citations

Medicine, Oncology, Pharmacology +15

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Paolo Ghia, Andrzej Pluta, Małgorzata Wach et al. · HemaSphere · 2022 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

Shambavi Richard, Ajai Chari, Sosana Delimpasi et al. · American Journal of Hematology · 2021 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Maurizio Martelli, Luca Ceriani, Giovannino Ciccone et al. · Journal of Clinical Oncology · 2024 · 28 citations · Full text

Medicine, Hematology, Oncology +16

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Holger W. Auner, Maria Gavriatopoulou, Sosana Delimpasi et al. · American Journal of Hematology · 2021 · 23 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14